Acute External Ventricular Drain Market Size, Share & Trends Analysis Report By Application (Traumatic Brain Injury (TBI), Subarachnoid Hemorrhage, Intracerebral Hemorrhage), By Patient Type, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global acute external ventricular drain market size was valued at USD 218.71 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.91% from 2022 to 2030. The growth is expected to be driven by increased demand for minimally or noninvasive neurosurgeries, rising prevalence of non-traumatic hydrocephalus, and rising adoption of technologically improved devices. According to NCBI, the use of EVD catheters in conjunction with intracranial pressure (ICP) monitoring has expanded recently, enabling the recording of ICP waveforms and values during continuous cerebrospinal fluid (CSF) drainage. As a result, the industry is anticipated to witness growth.

The market for the acute ventricular drain is anticipated to be moderately affected by the COVID-19 in the short run. Brain procedures have frequently been delayed or even canceled during this time to stop the coronavirus from spreading. Neurosurgical procedures decreased by 55% in the worst-affected countries, including the U.S., Italy, Russia, Brazil, France, the U.K., India, and Spain. These are some of the countries with the most confirmed cases and reported deaths.

Despite the COVID-19 pandemic, an increase in patients with traumatic brain injury (TBI), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), or other brain abnormalities that lead to increased Cerebrospinal fluid (CSF) build-up is expected to boost the demand for advanced acute external ventricular drainage devices, thus driving the market growth. Advanced devices might simplify surgical procedures, reduce treatment time, and aid in less invasive operations, resulting in market expansion in the near future.

For instance, in December 2019, Raumedic launched a new intracranial pressure monitoring device, Raumed home intracranial pressure, for home use. Such developments are likely to offer neurosurgeons more insights into therapy and enable patients suffering from hydrocephalus patients to lead a more active life. Hence, owing to the aforementioned factors, AEVD is expected to contribute to market growth, providing profitable opportunities for key players post COVID-19.

The increasing prevalence of neurological disorders, such as comprising cerebral hemorrhage with intraventricular extension, acquired brain injury, subarachnoid hemorrhage, hydrocephalus, aneurysm, traumatic brain injury (TBI), and meningitis, is expected to fuel market growth. Several of these conditions are associated with raised intracranial pressure (ICP) or intracranial hypertension above 20 mmHg due to obstruction of cerebrospinal fluid (CSF) outflow. External ventricular drain (EVD) is one of the most commonly performed neurosurgical procedures: More than 25,000 EVDs are inserted annually in the U.S. alone.

Moreover, EVD is frequently used in the management of TBI. EVD implantation has various advantages in TBI. For example, drainage of even modest quantities can considerably decrease ICP; assists in the clearance of hemorrhage from a ventricle, preventing recurrent hydrocephalus; and allows monitoring of ICP via the pressure transducer vent port, offering objective information to guide ICP/CPP-directed therapy. Thus, the rising prevalence of TBI is expected to raise the demand for EVD procedures. For instance, as per CDC data, in 2020, over 64,000 TBI-related fatalities occurred in the U.S., or 176 TBI-related fatalities every day.

Similarly, a research study published in Neurosurgical Focus in 2022 found that TBI affects up to 69 million people annually throughout the world. According to estimates, 1.6 million TBI cases that require neurosurgery happen each year in high-income countries (HICs), compared to 4.5 million cases in lower-middle-income countries (LMICS). Over 2.8 million Americans experience a TBI each year, with 280,000 of them necessitating hospitalization, according to a March 2021 article by the American Society for Biochemistry and Molecular Biology. TBI-related injuries cause close to 50,000 fatalities annually, or 155 fatalities each day. As a result, the high prevalence of TBI is anticipated to be a major driver of market expansion.

Several unique navigation techniques have lately been developed to overcome concerns regarding incorrect EVD placement, neurosonography smartphone-navigated placement, notably frameless stereotaxy, electromagnetic neuronavigation guidance, ultrasound-guided placement, optical neuronavigation, CT guidance, and wearable technologies. A smartphone augmented-reality mobile device application has already been developed, with or without a ventricular catheter-guiding instrument. The use of ultrasound navigation for EVD implantation has become the standard of treatment in the U.K. Ultrasound-guided EVD insertion reduces the possibility of malposition, decreasing the need for numerous insertions attempts and associated morbidities with multiple passes.

Therefore, manufacturers are involved continuously in developing advanced products which is anticipated to boost the industry’s growth in the forthcoming years. For instance, In July 2019, Integra LifeSciences acquired Arkis Biosciences, Inc., which is a private company that offers a portfolio of neurosurgical devices including the CerebroFlo External Ventricular Drainage (EVD) catheter with Endexo technology. This acquisition has strengthened Integra LifeScience’s Neuro-critical care segment.

The development of the coated external ventricular drain is another major factor that is expected to boost the market growth. The IDSA guideline and the American Neurocritical Care Society propose the use of coated EVDs to prevent ventriculitis to decrease infections associated with EVD. Antimicrobial catheters have been developed for EVDs; however, there have been a smaller number of clinical studies. For instance, in the U.S., VentriClear (Cook, Inc.) is an antibiotic-impregnated catheter containing rifampicin and minocycline, whereas Bactiseal (Codman Integra LifeSciences) includes rifampicin & clindamycin and is available internationally.

Several research studies and clinical trials are being conducted to prove the efficacy of coated EVD to reduce infections. In addition, coated EVDs have a higher cost than noncoated-EVDs; however, they are more effective in reducing the rate of infections and their use is cost-effective.

Application Insights

Based on application, the traumatic brain injury segment held the largest market share of 37.78% in 2021 and is expected to grow at the fastest CAGR from 2022 to 2030. Every year, more than 60 million new cases of traumatic brain injury are reported worldwide. The most common causes are car accidents and falls, both of which are on the rise.

TBI is associated with intracranial hemorrhage, which increases the risk of mortality and disability. The severity of such an injury might range from “mild,” which is defined as a transient change in mental status or consciousness, to “severe,” which is defined as an extended period of amnesia or unconsciousness following the damage. A TBI can cause short- or long-term issues with independent functions.

According to CDC, the number of TBIs has increased considerably over recent years. Based on the recent data, there were 16,070 TBI-related hospitalizations among children (birth to 17 years old) in 2019 and 2,774 TBI-related deaths in 2020. Moreover, the number and rate of TBI-related hospitalizations and deaths were higher among people aged 75 and over. This age group is responsible for around 28% of TBI-related deaths and 32% of TBI-related hospitalizations.

Thus, a high incidence of traumatic brain injuries leads to intraventricular bleeding (hemorrhage), which in turn demands the use of acute EVD products to remove excess cerebrospinal fluid from the brain. This in turn is expected to drive the market over the forecast period.

Patient Type Insights

The adult patient type segment held the largest revenue share of 83.97% in 2021. The prevalence of hydrocephalus has risen dramatically over time, raising the demand for EVD devices as a treatment option in adults. The increased frequency of neurological illnesses due to road accidents, falls, and violence all contribute to the external ventricular drain market's rapid expansion. For instance, as per the European Injury Database (IDB), approximately 6.1 million people are treated in hospitals for injuries every year. These injuries include facial and traumatic brain injuries.

Similarly, according to the CDC report, an estimated 56,000 older are hospitalized every year as a result of head injuries suffered due to falls and 775,000 older adults are living with TBI-related disabilities. This is expected to fuel segment growth during the forecast period. Moreover, growing research activities on diagnosis and surgical management along with a number of new pipelines of products are further boosting the industry growth.

The pediatric patient type segment is expected to grow at the fastest CAGR from 2022 to 2030. The increased frequency of neurological illnesses and other medical conditions, such as subarachnoid hemorrhages, hydrocephalus, intracranial hypertension, head injury, and inflammatory diseases of the cerebrospinal space, are expected to drive the segment.

Hydrocephalus affects one to two out of every 1,000 babies, according to the National Institute of Neurological Disorders and Stroke (NINDS). When the flow of cerebrospinal fluid inside the brain is impeded, an external ventricular drain device is used in neurosurgery to treat and alleviate elevated intracranial pressure and hydrocephalus. During the forecast period, this is expected to fuel market expansion.

Furthermore, various technological advancements and innovations, extensive research and development activities, and a large volume of clinical trials being conducted for the development of traumatic brain injuries and other diseases, as well as an increase in the number of falls and accident cases worldwide are expected to propel the segment growth.

Regional Insights

North America dominated the overall Acute EVD market in 2021 with a revenue share of around 35.48%. This can be attributed to the high prevalence of TBI and the high incidence of neurovascular illnesses in this region. Moreover, an increase in the number of FDA approvals for acute external ventricular drain products in clinical applications such as head injury, hydrocephalus, subarachnoid hemorrhages, and other diseases of cerebrospinal space are responsible for fueling the regional growth. In addition, increasing government funding and growing initiatives for raising awareness about neurological disorders are among the factors expected to drive the demand for external ventricular drain in this region.

In addition, favorable reimbursement structure and rising healthcare expenditure are factors contributing to the growth of the industry in the country. For instance, according to statistics published on CMS.gov, U.S. healthcare expenditure increased by 9.7% in 2020, reaching USD 4.1 trillion per person and accounting for a 19.7% share of the nation’s GDP. Thus, these factors are likely to boost the growth in the U.S. Furthermore, the favorable reimbursement structure is a major factor contributing to the growth.

Asia Pacific is expected to register the highest CAGR during the forecast period. Asia Pacific acute external ventricular drain market is primarily driven by the increasing incidence of sports injuries & trauma. Emerging economies, such as China, Japan, South Korea, and India, are expected to witness considerable market growth over the forecast period. The presence of a large patient pool and the growing need for technologically advanced & cost-efficient healthcare solutions are among the factors expected to present significant regional growth opportunities.

Moreover, the market is driven by high-impact R&D investments made by international businesses to reach underserved markets in Asia Pacific as a result of low-cost services and an increase in clinical trials. Other factors supporting market expansion in the region include an increase in hospital admissions and improvements in clinical development framework in developing nations. However, the region's expansion could be hampered by a lack of advanced healthcare facilities, a shortage of experienced experts, and a bad reimbursement environment.

Key Companies & Market Share Insights

Firms are also adopting several strategies such as collaborations, the launch of new products, and increasing their geographic footprint and distribution network by adopting the following strategic initiatives to gain a higher market share. For instance, in October 2021, RAUMEDIC announced the expansion of its manufacturing unit in Mills River, North Carolina, U.S. by February 2022. Similarly, in the same month, Spiegelberg announced its new sales partner LaboClinic for Poland. This is expected to help the company increase its presence in Poland. The pandemic has also created opportunities for local manufacturers. Thus, the market is expected to grow at a considerable rate in the coming years. Some prominent players in the global acute external ventricular drain market include:

• Medtronic

• Integra LifeSciences Corporation

• Natus Medical Incorporated

• Fuji Systems

• Spiegelberg GmbH

• SOPHYSA

• Neuromedex

Acute External Ventricular Drain Market Report Scope

Global Acute External Ventricular Drain Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global acute external ventricular drain market report based on application, patient type, and region:

• Application Outlook (Revenue, USD Million, 2017 - 2030)

  • Traumatic Brain Injury

  • Subarachnoid Hemorrhage

  • Intracerebral Hemorrhage

  • Other Non-traumatic Hydrocephalus Conditions

• Patient Type Outlook (Revenue, USD Million, 2017 - 2030)

  • Pediatric

  • Adult

• Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE